DrugPatentWatch Database Preview
Genus Company Profile
» See Plans and Pricing
What is the competitive landscape for GENUS, and what generic alternatives to GENUS drugs are available?
GENUS has ten approved drugs.
There are fourteen US patents protecting GENUS drugs.
There are eighty patent family members on GENUS drugs in twenty-eight countries and twenty-five supplementary protection certificates in thirteen countries.
Summary for Genus
| International Patents: | 80 |
| US Patents: | 14 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 10 |
| Patent Litigation for Genus: | See patent lawsuits for Genus |
Drugs and US Patents for Genus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-003 | Jun 6, 2003 | DISCN | No | No | Start Trial | Start Trial | |||||
| Genus Lifesciences | GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963-001 | Dec 14, 2017 | RX | Yes | Yes | 10,231,961 | Start Trial | Y | Start Trial | |||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-011 | Jun 6, 2003 | DISCN | No | No | Start Trial | Start Trial | |||||
| Genus | TIVORBEX | indomethacin | CAPSULE;ORAL | 204768-001 | Feb 24, 2014 | RX | Yes | No | 9,089,471 | Start Trial | Start Trial | ||||
| Genus | TIVORBEX | indomethacin | CAPSULE;ORAL | 204768-002 | Feb 24, 2014 | RX | Yes | Yes | 8,734,847 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for GENUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 81 mg/40 mg | ➤ Subscribe | 2016-10-14 |
International Patents for Genus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2010239081 | Start Trial |
| Mexico | 2014007935 | Start Trial |
| Morocco | 32692 | Start Trial |
| Israel | 215872 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2010029335 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1411900 | 122012000052 | Germany | Start Trial | PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 |
| 0733366 | SPC/GB98/031 | United Kingdom | Start Trial | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| 0809498 | SPC/GB10/012 | United Kingdom | Start Trial | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 1441735 | SPC/GB08/020 | United Kingdom | Start Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
| 1411900 | C300481 | Netherlands | Start Trial | PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
